Document:

Separation Agreement Amendment between Stuart W. Booth and Central Garden & Pet

 Exhibit 10.1 
 Amendment to Separation Agreement 
 This Separation Agreement
Amendment dated January 14, 2010 (“Separation Amendment”) is entered by and among Central Garden & Pet Company, its, subsidiaries, affiliates and related entities (“Central” or “Company”) and Stuart W.
Booth (“Executive”). 
 WHEREAS, Executive was formerly employed as Executive Vice President, Chief Financial Officer and Secretary of
Central; 
 WHEREAS, Executive and Central entered into a Separation Agreement and General Release of All Claims on April 1, 2009
(“Separation Agreement”) related to Executive’s resignation from the Company; 
 WHEREAS Executive currently serves as a
consultant to Central; 
 WHEREAS, the parties desire Executive to return to full-time employment with Central in a temporary, interim Chief
Financial Officer (“CFO”) position until a replacement executive is hired and a transition is complete; 
 THEREFORE, for good and
adequate consideration including the covenants contained herein, the Parties agree as follows: 
  

	1.	Prior Agreement. The Separation Agreement is incorporated herein by reference and shall continue in effect except as provided herein. Where there is a conflict
between the Separation Agreement and this Separation Amendment, this Separation Amendment shall control. 

  

	2.	Executive will be re-employed in the position of CFO until a replacement executive is hired and for a reasonable transition period thereafter as requested by the
Company, the combined period to be a minimum of six (6) months, and month to month thereafter up to a maximum of twelve (12) months unless the parties mutually agree to extend the period in writing. The period commencing with the New
Effective Date of this Separation Amendment and continuing until the New Termination Date will be referred to as the “New Transition Period”. 

  

	3.	During the New Transition Period the Company will pay Executive an annualized salary of four hundred thousand dollars ($400,000) and the same benefits as provided
during the Transition Period in the Separation Agreement. Executive also will receive a “transition bonus” of $16,666.66 per month for each full month worked, payable on the New Termination Date. 

  

	4.	Effective January 15, 2010, Executive will receive a grant of fifty thousand (50,000) Class A stock options pursuant to a Non-Qualified Stock Option
Agreement under the Company’s 2003 Equity Incentive Plan. This award will vest as set forth in the stock option agreement and the Separation Agreement. 

  

 1 

			
	Stu Booth Separation Agreement	  	Initial
Executive SWB         Company WEB        

	5.	At the conclusion of the New Transition Period Executive’s employment will be considered terminated for all purposes (“New Termination Date”).

  

	6.	Commencing on the New Effective Date of this Separation Amendment, the severance of $31,667 referred to in paragraph 6 of the Separation Agreement shall be modified to
$33,333.33 per month. 

  

	7.	The term “eighteen (18) months” in paragraphs 7 and 8 of the Separation Agreement shall be modified to “twenty two (22) months.”

  

	8.	Commencing on the New Effective Date of this Separation Amendment, all references to the “Transition Period” in the Separation Agreement will have the same
meaning as the term “New Transition Period” in this Separation Amendment. 

  

	9.	Commencing on the New Effective Date of this Separation Amendment, all references to the “Termination Date” in the Separation Agreement will have the same
meaning as the term “New Termination Date” in this Separation Amendment. 

  

	10.	Paragraph 9(a) of the Separation Agreement is amended and clarified to read as follows: 

  

	 	(a)	Group Insurance: The Company will pay for Executive’s COBRA health insurance continuation coverage for Executive, Executive’s spouse and eligible
dependents for eighteen (18) months after he ceases to receive the severance payments from the Company provided in Paragraph 6 above. Executive will pay an amount for this COBRA coverage comparable to the employee contribution amounts paid by
senior executives of the Company. Thereafter, the Company will continue comparable health insurance coverage through HIPPA coverage for Executive, Executive’s spouse and Executive’s eligible dependents until Executive’s spouse reaches
the age of sixty six (66), i.e. 070/7/2019 or until they become eligible for coverage under another group health care plan, whichever comes first. The Company’s contribution to such coverage will be the actual expense of such coverage up to a
maximum of $1,400 per month. The Company’s payments for health insurance continuation coverage will be considered income to the Executive for tax reporting purposes. 

  

	11.	Executive and Central agree to re-execute this Separation Amendment on the New Termination Date. Executive will not receive his transition bonus, severance and benefits
following the New Termination Date unless he re-executes this Separation Amendment. Executive and Central understand that by re-executing this Separation Amendment after the New Termination Date they are renewing and reaffirming all the terms of the
Separation Agreement as modified herein, including but not limited to the general release provisions. 

 // 
 // 
 // 
  

 2 

			
	Stu Booth Separation Agreement	  	Initial
Executive SWB         Company WEB        

	12.	This Separation Amendment will become effective (“New Effective Date”) when it is signed by all parties. 

  

							
	Date: 1/14/2010	 		 		 	 /s/ Stuart W. Booth

		 		 		 	Stuart W. Booth
				
	Date: 1/14/2010	 		 		 	 /s/ William E. Brown

		 		 		 	Central Garden & Pet Company
				
	Re-executed:	 		 		 	
				
	Dated:                     	 		 		 	  

		 		 		 	Stuart W. Booth
				
	Date:                     	 		 		 	  

		 		 		 	Central Garden & Pet Company

  

 3 

			
	Stu Booth Separation Agreement	  	Initial
Executive SWB         Company WEBThird Agreement Regarding Private Placement of Securities

 Exhibit 10.67 
 THIRD AGREEMENT REGARDING PRIVATE PLACEMENT OF SECURITIES 
 OF 
 SUNESIS PHARMACEUTICALS, INC. 
 THIS AGREEMENT (the “Agreement”) is made and entered into as of this 19th day
of January, 2010, by and among SUNESIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and the persons and entities listed on
Exhibit A hereto (the “Investors”). 
 RECITALS 
 A. The Company and the Investors wish to amend that certain Securities Purchase Agreement, dated March 31, 2009, as amended on
June 29, 2009 and October 27, 2009 (as amended, the “Purchase Agreement”), by and among the Company and the Purchasers (as defined in the Purchase Agreement); 
 B. Pursuant to Section 7.4 of the Purchase Agreement, the Purchase Agreement may be amended only by a written instrument signed
by the Company and the Purchaser or Purchasers holding or having the right to acquire, at the time of such amendment, at least a majority-in-interest of the total Unit Shares (as defined in the Purchase Agreement); 
 D. The undersigned hold or have the right to acquire at least a majority-in-interest of the total Unit Shares (collectively, the
“Requisite Investors”). 
 AGREEMENT 
 NOW, THEREFORE, in consideration of these premises and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 1.
AMENDMENT TO PURCHASE AGREEMENT. 
 1.1 The Company and
the undersigned hereby agree that the definition of “Purchaser Put Notice” in Section 1.1 of the Purchase Agreement is hereby amended and restated to read as follows: 
 “‘Purchaser Put Notice’ means a written notice by the Lead Purchasers to the Company and all
Purchasers, which shall be delivered if the Majority Purchasers elect to consummate the Common Equity Closing and shall set forth such election, delivered (i) at any time prior to January 8, 2010, (ii) on or before January 15,
2010, if a Cash Balance Notice is delivered no later than January 12, 2010 and such Cash Balance Notice reflects a Cash balance of less than $2.5 million as of January 8, 2010 or (iii) if a Cash Balance Notice delivered no later than
January 12, 2010 sets forth the Company’s Cash balance as greater than $2.5 million as of January 8, 2010, at any time prior to the earlier of (A) June 30, 2010, (B) five (5) Trading Days following the
delivery to the Lead Purchasers of a Cash Balance Notice reflecting a Cash balance of the Company of less than $2.5 million and (C) the closing of an Alternative Common Stock Financing.” 
 1.2 The Company and the undersigned hereby agree that Section 2.1(a)(iii) of the Purchase Agreement is hereby amended and
restated to read as follows: 
 “(iii) Common Equity Closing. Provided that the Stockholder
Approval has been obtained, following the First Unit Closing and the earlier of (i) delivery by the

  

 1. 

 
Company of written notice to the Purchasers of the election by the Company to consummate the Common Equity Closing on or before the earlier of (A) the delivery of a Purchaser Put Notice,
(B) the consummation of an Alternative Common Stock Financing and (C) June 30, 2010 (the “Company Election Notice”) and (ii) delivery by the Lead Purchasers of the Purchaser Put Notice (in the case
of either (i) or (ii) above, the “Common Equity Closing Notice”), the Company shall issue and sell to each Purchaser, and each Purchaser shall, severally and not jointly, purchase from the Company, such number of
shares of Common Stock equal to the quotient resulting from dividing (i) the Common Equity Closing Subscription Amount for such Purchaser by (ii) the Common Per Share Purchase Price, rounded down to the nearest whole share (the
“Pro Rata Share”); provided, however, that the Purchasers shall have no obligation to purchase the Common Equity Shares if the Majority Purchasers provide written notice to the Company within ten (10) Trading Days
following the delivery of the Company Election Notice, that the Purchasers will not participate in the Common Equity Closing (the “Non-Participation Notice”) or if the gross amount to be received at the Common Equity Closing
is less than the Minimum Aggregate Common Equity Subscription Amount, taking into account any agreement by a Purchaser to purchase more than its Pro Rata Share of the shares of Common Stock to be sold in the Common Equity Closing, and
the Company is unable to secure additional purchasers, acceptable to the Lead Purchasers, to participate in the Common Equity Closing such that the Minimum Aggregate Common Equity Subscription Amount is met. The delivery of the Company Election
Notice shall be in the sole discretion of the Board, and the delivery of the Non-Participation Notice or the Common Equity Closing Notice shall be in the sole discretion of the Majority Purchasers. There shall be no obligation on the part of
the Majority Purchasers to elect to consummate the Common Equity Closing and, by extension, to cause the Lead Purchasers to deliver a Purchaser Put Notice, but if such Purchaser Put Notice is delivered, or a Non-Participation Notice is not timely
delivered following a Common Equity Closing Notice, each Purchaser shall be obligated to purchase its Pro Rata Share of the shares of Common Stock to be sold in the Common Equity Closing, and if a Purchaser Put Notice is delivered, the Company shall
be obligated to sell the shares of Common Stock to be sold in the Common Equity Closing. In the event that any Purchaser does not satisfy the foregoing obligation, the other Purchasers shall have the right, but not the obligation, to purchase
the Pro Rata Portion of such defaulting Purchaser. Notwithstanding any other provision of this Agreement, in the event the Common Equity Closing is consummated, if any Purchaser fails to purchase its Pro Rata Share of Common Stock in such
Common Equity Closing, then such Purchaser’s Preferred Stock shall automatically be converted into Common Stock in such amounts and on such terms as provided in Section 4(m) of the Certificate of Designation, which shall be the
Company’s and each other Purchaser’s sole and exclusive remedy for such Purchaser’s failure to purchase its Pro Rata Share in the Common Equity Closing. No later than January 12, 2010, the Company shall deliver to the Lead
Purchasers a Cash Balance Notice reflecting the Company’s Cash balance as of January 8, 2010 and, if such Cash Balance Notice sets forth the Company’s Cash balance as greater than $2.5 million as of January 8, 2010, the
Lead Purchasers may request until such time as the Company delivers a Cash Balance Notice that sets forth the Company’s Cash balance as less than $2.5 million (in which case the Company shall promptly deliver such requested Cash Balance
Notice, which shall be dated as of a recent practicable date), or the Company may elect to deliver one or more future Cash Balance Notice(s) at any time prior to the earlier of June 30, 2010 and the closing of an Alternative Common Stock
Financing.” 
  

 2. 

 2. MISCELLANEOUS. Any capitalized terms used but not defined
herein shall have the meanings ascribed to them in the Purchase Agreement. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
A facsimile, telecopy or other reproduction of this Agreement may be executed by one or more parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of
such party can be seen. Such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute and deliver an original of this Agreement as well as any
facsimile, telecopy or other reproduction hereof. Other than as set forth herein, the Purchase Agreement shall remain in full force and effect. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by and construed and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of law thereof. Upon the execution of this Agreement by the Company and the Requisite
Investors, all parties to the Purchase Agreement shall be bound by this Agreement. 
 [Signature Pages Follow] 

 

 3. 

 IN WITNESS WHEREOF, the
parties hereto have executed this Agreement as of the date first above written. 
  

									
	COMPANY:	 		 	INVESTORS:
			
	SUNESIS PHARMACEUTICALS, INC.	 		 	BAY CITY CAPITAL FUND V, L.P.
					
	Signature:	 	 /s/    Daniel N. Swisher, Jr.
	 		 	By:	 	 /s/    Carl Goldfischer

	Print Name:	 	Daniel N. Swisher, Jr.	 		 	Name:	 	Carl Goldfischer
	Title:	 	President and CEO	 		 	Title:	 	Managing Director
	Address:	 	395 Oyster Point Boulevard, #400	 		 		 	
		 	South San Francisco, CA 94080	 		 		 	
				
		 		 		 	BAY CITY CAPITAL FUND V CO-INVESTMENT FUND,
L.P.
					
		 		 		 	By:	 	 /s/    Carl Goldfischer

		 		 		 	Name:	 	Carl Goldfischer
		 		 		 	Title:	 	Managing Director

 SUNESIS PHARMACEUTICALS, INC. 

 THIRD AGREEMENT REGARDING PRIVATE PLACEMENT
OF SECURITIES – SIGNATURE PAGE 

			
	GROWTH EQUITY OPPORTUNITIES FUND, LLC
		
	By:	 	 /s/    Charles W. Newton, III

	Name:	 	Charles W. Newton, III
	Title:	 	Manager of NEA 12 GP, LLC, which is the general partner of NEA Partners 12, L.P., which is the sole general partner of New Enterprise Associates 12, L.P., the sole member of
Growth Equity Opportunities Fund, LLC

 SUNESIS PHARMACEUTICALS, INC.

 THIRD AGREEMENT REGARDING PRIVATE PLACEMENT
OF SECURITIES – SIGNATURE PAGE 

			
	ALTA BIOPHARMA PARTNERS III, L.P.
		
	By:	 	Alta BioPharma Management III, LLC
		
	By:	 	 /s/    Ed Hurwitz

	Name:	 	Ed Hurwitz
	Title:	 	Director
	
	ALTA BIOPHARMA PARTNERS III GMBH & CO. BETEILIGUNGS
KG
		
	By:	 	Alta BioPharma Management III, LLC
		
	By:	 	 /s/    Ed Hurwitz

	Name:	 	Ed Hurwitz
	Title:	 	Director
	
	ALTA EMBARCADERO BIOPHARMA PARTNERS III, LLC
		
	By:	 	 /s/    Ed Hurwitz

	Name:	 	Ed Hurwitz
	Title:	 	Manager

 SUNESIS PHARMACEUTICALS, INC.

 THIRD AGREEMENT REGARDING PRIVATE PLACEMENT
OF SECURITIES – SIGNATURE PAGE 

			
	SWISHER REVOCABLE TRUST
		
	By:	 	 /s/    Daniel N. Swisher, Jr.

	Name:	 	Daniel N. Swisher, Jr.
	Title:	 	Trustee

 SUNESIS PHARMACEUTICALS, INC.

 THIRD AGREEMENT REGARDING PRIVATE PLACEMENT
OF SECURITIES – SIGNATURE PAGE 

			
	BJERKHOLT/HAHN FAMILY TRUST
		
	By:	 	 /s/    Eric Bjerkholt

	Name:	 	Eric Bjerkholt
	Title:	 	Trustee

 SUNESIS PHARMACEUTICALS, INC.

 THIRD AGREEMENT REGARDING PRIVATE PLACEMENT
OF SECURITIES – SIGNATURE PAGE 

			
	STEVEN BLAKE KETCHUM
		
	By:	 	 /s/    Steven Blake Ketchum

 SUNESIS PHARMACEUTICALS, INC.

 THIRD AGREEMENT REGARDING PRIVATE PLACEMENT
OF SECURITIES – SIGNATURE PAGE 

 EXHIBIT A 
 LIST OF INVESTORS 
 Bay
City Capital Fund V, L.P. 
 Bay City Capital Fund V Co-Investment Fund, L.P. 
 Growth Equity Opportunities Fund, LLC 
 Alta BioPharma Partners III, L.P. 
 Alta BioPharma Partners III GmbH & Co. Beteiligungs KG 
 Alta Embarcadero BioPharma Partners III, LLC 
 Swisher Revocable Trust 
 Bjerkholt/Hahn Family Trust 
 Steven Blake Ketchum

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}]]